If you use your blue inhaler frequently, wake up coughing at night or believe your asthma is "controlled" just because flare-ups appear occasionally, the GINA 2026 update may completely change the way you understand the disease.
The new international GINA (Global Initiative for Asthma) guideline, released in May 2026, brought important changes to asthma treatment, especially regarding the use of the famous relief inhaler.
And the main message is direct:
Asthma should no longer be treated only when a flare-up appears.
Today, experts from around the world emphasise that asthma inflammation can remain active even when a person "seems well". This means that many patients considered to have mild asthma may still have a risk of severe attacks, hospitalisations and respiratory complications.
What is GINA and why does this update matter?
GINA is a global initiative formed by experts in pneumology and allergy who annually review the main scientific studies on asthma in the world.
GINA recommendations influence:
• doctors
• hospitals
• emergency protocols
• treatments used in clinics
• and health policies in various countries
The 2026 update reinforced a change that had been growing over recent years:
using only relief bronchodilator is no longer considered the safest treatment for the majority of asthma patients.
"But I've always used only the relief inhaler…"
Case study: the patient who thought she was controlled
Mariana, 28 years old, used salbutamol only when she felt short of breath.
She said:
"My asthma is mild. It only attacks sometimes."
Until a simple flu progressed to an intense attack, requiring nebulisation and a trip to the emergency room.
The problem is that salbutamol:
• improves symptoms quickly
• but does not treat lung inflammation
It's like turning off the warning light on the car's dashboard without fixing the engine fault.
And that's exactly what GINA 2026 tries to prevent.
The major change of GINA 2026: treating inflammation from the start
The update reinforces the early use of medications with inhaled corticosteroid, even in patients with mild symptoms.
Among the treatments that gained prominence are combinations such as:
• budesonide + formoterol
• inhaled corticosteroid associated with rapid-acting bronchodilator
In practice:
• one medication helps open the lungs
• the other reduces asthma inflammation
And this reduces:
• severe attacks
• need for oral corticosteroid
• hospital visits
• risk of hospitalisation
• and even risk of death from asthma
"Does inhaler with corticosteroid cause harm?"
This is still one of the most searched questions on Google.
Case study: the patient who was afraid of treatment
Carlos avoided using budesonide because he heard that "corticosteroid is harmful".
So he spent months using his relief inhaler several times a day.
Result:
• progressive worsening of inflammation
• more wheezing
• more shortness of breath
• more attacks
The major difference is that inhaled corticosteroid acts directly on the lung, in much smaller doses than tablets or injections.
That's why, when used correctly and with medical supervision, it is usually safer than living in constant crisis.
Asthma treatment now works in stages
GINA divides asthma into levels of control.
The greater the symptoms, the greater the intensity of treatment.
Stage 1: occasional symptoms
Patient who wheezes sometimes or feels short of breath during exercise.
Before:
• relief inhaler only
Now:
• preference for medications that already control inflammation
Stage 2: frequent symptoms
Nighttime cough, recurrent wheezing and greater need for the inhaler.
This includes:
• low-dose inhaled corticosteroids
• or combination therapy
Stage 3: frequent inhaler use
Patients who begin to limit physical activity or have weekly symptoms.
GINA reinforces SMART/MART treatment:
• the same inhaler serves for control and relief
This simplifies treatment and reduces severe attacks.
Stages 4 and 5: moderate and severe asthma
Patients with:
• repeated attacks
• hospitalisations
• constant corticosteroid use
• significant breathing limitation
This may include:
• higher doses of medication
• additional bronchodilators
• and modern immunobiological agents
Among them:
• omalizumab
• dupilumab
• mepolizumab
• benralizumab
These treatments represent one of the greatest advances in pneumology in recent years.
Another important change of GINA 2026: children
The update also reinforced new ways to assess the severity of childhood asthma.
This helps doctors to quickly identify:
• which children have greater risk
• who needs hospitalisation
• and which cases can be safely treated at home
The biggest mistake among those with asthma today
Many people believe that:
"If I only have attacks sometimes, then my asthma is controlled."
But the new guideline makes clear:
• mild symptoms do not mean low risk
• silent inflammation may still exist
• and relying only on the relief inhaler can be dangerous
When to see a doctor?
Seek evaluation if you:
• use your inhaler frequently
• wake up coughing
• feel wheezing in your chest
• avoid exercise due to shortness of breath
• have already needed to go to the emergency room
• or have attacks after flu, dust or climate change
Important
This content is informational and does not replace medical consultation, diagnosis or individualised treatment.
Each patient has their own characteristics, and the ideal treatment should be defined after appropriate medical evaluation.
If you have respiratory symptoms or suspect asthma, seek a healthcare professional.
Dr. Rebeca Soares Andrade CRM-GO 39335